Updated

Novartis is facing a challenge to build its next generation of blockbuster medicines after a series of disappointing clinical trial results, CNBC Top News reported on October 30, 2026. The pharmaceutical company is moving past one patent cliff, but another is already looming. The report highlights pressure on the company to replace revenue from drugs losing patent protection. The sources provided do not give specific trial names or market reaction.